Myriad Genetics (MYGN) EBIAT: 2009-2025
Historic EBIAT for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$27.4 million.
- Myriad Genetics' EBIAT fell 23.98% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of -$127.3 million for FY2024, which is 51.65% up from last year.
- As of Q3 2025, Myriad Genetics' EBIAT stood at -$27.4 million, which was up 91.71% from -$330.5 million recorded in Q2 2025.
- Over the past 5 years, Myriad Genetics' EBIAT peaked at $24.6 million during Q3 2021, and registered a low of -$330.5 million during Q2 2025.
- Over the past 3 years, Myriad Genetics' median EBIAT value was -$36.7 million (recorded in 2024), while the average stood at -$68.1 million.
- Per our database at Business Quant, Myriad Genetics' EBIAT skyrocketed by 261.84% in 2021 and then crashed by 800.54% in 2025.
- Over the past 5 years, Myriad Genetics' EBIAT (Quarterly) stood at -$7.6 million in 2021, then slumped by 456.58% to -$42.3 million in 2022, then increased by 26.24% to -$31.2 million in 2023, then slumped by 36.22% to -$42.5 million in 2024, then declined by 23.98% to -$27.4 million in 2025.
- Its EBIAT stands at -$27.4 million for Q3 2025, versus -$330.5 million for Q2 2025 and -$100,000 for Q1 2025.